Intas Pharmaceuticals Limited (manufacturing of medicinal product, primary and secondary packaging)

The drug is prescribed to adult patients who are not candidates for stem cell transplantation for the treatment of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).

Dosage form: powder for injection suspension

ATC: L01BC07

The drug is intended for the treatment of adult patients who are not candidates for stem cell transplantation, for the following diseases: intermediate and high-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) with a certain blast content in the bone marrow, as well as acute myeloid leukemia (AML).

Dosage form: powder for injection suspension

ATC: L01BC07

The drug is used as part of conditioning therapy prior to hematopoietic stem cell transplantation (HSCT). It is prescribed to adults and children in combination with other drugs (e.g., cyclophosphamide, melphalan, or fludarabine) depending on the treatment regimen.

Dosage form: concentrate for infusion solution

ATC: L01AB01